Accessibility StatementSkip Navigation About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertis ...

Core Insights - Sai Life Sciences Limited reported strong financial performance for Q1FY26, with revenue reaching ₹496 crore, a 77% increase year-over-year, driven by growth in the CDMO segment [1][2][8] - The company achieved an EBITDA of ₹125 crore, reflecting a 305% increase compared to the same quarter last year, with an EBITDA margin of 25% [2][6][8] - Net profit for the quarter was ₹60 crore, a significant turnaround from a loss of ₹13 crore in Q1FY25, resulting in a PAT margin of 12% [2][6][8] Financial Performance - Revenue from Operations: ₹496 crore in Q1FY26 compared to ₹280 crore in Q1FY25, a 77% increase [2][6] - EBITDA: ₹125 crore in Q1FY26, up from ₹31 crore in Q1FY25, a 303% increase [2][6] - EBITDA Margin: Expanded to 25% in Q1FY26 from 11% in Q1FY25 [2][6] - Profit Before Tax (PBT): ₹81 crore in Q1FY26, compared to a loss of ₹18 crore in Q1FY25 [2][6] - Profit After Tax (PAT): ₹60 crore in Q1FY26, compared to a loss of ₹13 crore in Q1FY25 [2][6] Business Highlights - The company inaugurated new Biology Labs and a Peptide Research Center, enhancing its Integrated Discovery platform [6][9] - Commenced commercial operations at Bidar Unit IV, increasing total manufacturing capacity to approximately 700 KL [6][9] - Invested ₹134 crore in capital expenditure during Q1FY26, focusing on R&D infrastructure and process development capabilities [6][9] - Onboarded 253 scientists and technical staff to support scaling operations [6][9] Strategic Focus - The company is committed to advancing innovation in complex science and enhancing client partnerships [5][7] - Plans to build additional production capacity at Unit IV, Bidar, expected to be ready by Q3FY27 [6][9] - Ongoing construction of a new Medicinal Chemistry block to support early-phase peptide development and clinical formulations [6][9]